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Abstract
OBJECTIVE—To determine whether there is a threshold 3-hour OGTT value associated with 
accelerated risk of adverse pregnancy outcomes.
STUDY DESIGN—In a secondary analysis of a cohort of women with untreated mild gestational 
glucose intolerance, defined as 50 gram glucose loading test between 135 and 199 mg/dL and 
fasting glucose <95 mg/dL, we used generalized additive models with smoothing splines to 
explore non-linear associations between each of the 3-hour OGTT values (fasting, 1-h, 2-h, and 3-
h) and adverse pregnancy outcomes, including the study’s composite outcome (perinatal mortality, 
hypoglycemia, hyperbilirubinemia, neonatal hyperinsulinemia, and/or birth trauma), large-for-
gestational age birth weight, small-for-gestational age birth weight, shoulder dystocia, neonatal 
hypoglycemia, gestational hypertension and preeclampsia.
RESULTS—Among 1360 eligible women, each timed OGTT value was linearly associated with 
increased odds of composite adverse outcome. We found evidence of a departure from linearity 
only for the association between fasting glucose and gestational hypertension/preeclampsia 
(gHTN), with a stronger association for values of 85-94 mg/dL (p=0.03). We found no evidence of 
departure from linearity for any other OGTT values and measured outcomes (all chi-square test p-
values ≥0.05).
CONCLUSION—In a population of untreated women with mild gestational glucose intolerance 
and fasting OGTT < 95 mg/dL, we found an increasing risk of gestational hypertension with 
fasting glucose between 85 and 94 mg/dL.
Keywords
maternal glycemia; gestational diabetes; GDM
Introduction
Gestational diabetes (GDM) affects 2.2 to 8.8 percent of pregnant women. Treatment of 
impaired glucose tolerance during pregnancy, whether with diet, oral hypoglycemics, or 
insulin, can reduce perinatal morbidity and may also reduce the infant’s risk of obesity in 
later life 1, 2.
Since O’Sullivan first described gestational glucose intolerance3, progressively lower 
thresholds have been used to make the diagnosis of gestational diabetes. Recent data from a 
large, observational cohort study demonstrated that the risk of adverse outcomes increases 
with increasing glucose values, even among women with sub-threshold results in fasting and 
2-hour post-load glucose screening4. These results have led to lower proposed thresholds for 
diagnosis and treatment of gestational diabetes5. It is not known, however, whether there is a 
glucose tolerance threshold above which there is an acceleration in risk of adverse 
outcomes. Such a glucose threshold could be used as a natural cut-point to identify women 
at elevated risk of adverse outcomes.
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We therefore tested whether there is non-linear relationship between glucose tolerance 
measured on the 3-hour oral glucose tolerance test and adverse pregnancy outcomes in a 
cohort of women with untreated mild gestational glucose intolerance.
Methods
We performed a secondary analysis of women with untreated mild gestational glucose 
intolerance. Participants were derived from two groups: 1) women randomized to no 
treatment in the previously reported Eunice Kennedy Shriver National Institute of Child 
Health and Human Development Maternal-Fetal Medicine Units Network multicenter 
randomized trial of treatment for mild gestational diabetes (GDM); and 2) women in the 
associated observational cohort, comprised of women with a 50-gram glucose screen ≥ 135 
mg/dL who did not meet criteria for gestational diabetes. 1
To be eligible for participation in the primary study, women had to be between 24 weeks 0 
days and 30 weeks 6 days gestation and have a 50-gram glucose loading test screen between 
135 and 199 mg/dL. Eligible women underwent diagnostic testing with a 100-gram 3-hour 
OGTT. Women with normal fasting values (< 95 mg/dL) but at least 2 OGTT values 
exceeding established thresholds (1h 180 mg/dL, 2h 155 gm/dL, 3h 140 mg/dL) were 
randomized to treatment for mild GDM or usual care. In addition, women with normal 
OGTT results were followed in an observational cohort. In the primary study, participants in 
the observational cohort were frequency matched at each participating center to the GDM 
group by body mass index < or ≥ 27 kg/m2 and race/ethnicity (black, Hispanic, or non-
black, non-Hispanic). Further details of the methodology of the study have been described 
elsewhere.1 Women were excluded from the primary study if they had any of the following 
conditions: preexisting diabetes, an abnormal result on a glucose screening test < 24 wks, or 
prior GDM; history of stillbirth, multifetal gestation, asthma, or chronic hypertension; active 
corticosteroids use; fetus with a known fetal anomaly, or were likely to have an imminent 
preterm delivery.
For the current analysis, we included women who were randomized to usual care or who 
were enrolled in the observational cohort (N=1360) in order to study the natural history of 
blood glucose concentration in the absence of treatment. For outcome vs. OGTT analyses, 
women with missing values for an outcome were excluded from the analysis for that 
outcome (primary outcome, N=57; gestational hypertension/preeclampsia, N=1; 
preeclampsia, N=1; LGA, N=1; SGA, N=1; shoulder dystocia, N=0; and neonatal 
hypoglycemia, N=288).
Measurement of exposures
Maternal glucose tolerance was measured using the 100-gram 3-hour Oral Glucose 
Tolerance Test (OGTT) after an overnight fast. Maternal age, self-reported race/ethnicity 
and parity were obtained by patient interview at the time of enrollment. Gestational age was 
confirmed by ultrasound prior to the OGTT
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In this secondary analysis, we measured the association between maternal OGTT results and 
the primary outcome of the parent study, as well as gestational hypertension/preeclampsia, 
preeclampsia, LGA, SGA, shoulder dystocia, and neonatal hypoglycemia. The primary 
outcome of the parent study was a composite outcome of perinatal mortality, hypoglycemia, 
hyperbilirubinemia, neonatal hyperinsulinemia, or birth trauma1. Gestational hypertension 
was defined as systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm 
Hg or more on two occasions at least 4 hours apart, or one elevated blood-pressure value 
subsequently treated with medication. Preeclampsia was defined as elevation in blood 
pressure, as defined for gestational hypertension, with proteinuria (≥ 300 mg of protein / 24-
hour collection or dipstick ≥2+ if 24-hour collection not available) or with AST ≥ 70 U/L or 
platelet count < 100,000/L. Large for gestational age (LGA) birth weight was defined as > 
90% for gestational age, and small for gestational age (SGA) was defined as birth weight < 
10% for gestational age6.
Analysis
Statistical analyses were performed using SAS statistical software (SAS Institute, Cary, NC) 
and R (www.r-project.org). We used the generalized additive models (GAM) with 
smoothing splines7 to explore non-linear associations between each 3-hour OGTT parameter 
and adverse outcome. Generalized additive models use non-parametric techniques to 
identify non-linear relationships between an exposure and an outcome. For example, both 
adolescent pregnancy and advanced maternal age are associated with adverse pregnancy 
outcomes, compared with pregnancies in women in their 20s and 30s. A simple logistic 
regression model measuring the association between maternal age and adverse pregnancy 
outcome would not detect this association, because it assumes a linear relationship between 
age and outcome, while a general additive model could detect a U-shaped association 
between these two variables. For the present analysis, we allowed for such departures from 
linearity, allowing for associations between OGTT values and outcome to increase, decrease 
or plateau across the range of values observed. If such an inflection point were identified, it 
might provide a natural cut-point for diagnosing pathological glucose intolerance. We set 
two as the target equivalent degrees of freedom (smoothing parameter). We considered a 
departure from linearity to be significant if the chi-square test for the non-linear splines 
showed a p-value < 0.05. If no non-linear association was found, we reduced the model to 
logistic regression with a linear term for each 3-hour OGTT parameter. We present figures 
with unadjusted predicted probabilities and 95% confidence intervals for each outcome for 
which we found a statistically significant association in order to illustrate their clinical utility 
for risk stratification. All models quantified the univariate association between an OGTT 
parameter and outcome, without adjustment for other factors.
Results
Of the 1360 participants eligible for inclusion in our study, 775 were Hispanic (57.0%), 362 
were white (26.6%), 165 were black (12.1%) and 58 were of other race/ethnicity (4.3%). 
The mean maternal age was 27.9 (SD 5.6), and 32.9% were nulliparous (Table 1). About 1/3 
of participants met criteria for composite adverse neonatal outcome (Table 2).
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In our generalized additive models, we found no evidence of a non-linear association 
between any OGTT parameter and composite adverse neonatal outcome, preeclampsia, 
LGA, SGA, shoulder dystocia, or neonatal hypoglycemia (all chi-square test p-values ≥ 
0.05). We did find evidence of non-linearity for the association between fasting glucose and 
gestational hypertension/preeclampsia, with an increase in the slope of the association for 
glucose values between 85 and 94 (chi-square test p-value=0.03). Within our study 
population, 59.4% had a glucose value between 85 and 94.
We found linear associations between 3-hour OGTT parameters and the primary outcome 
(all OGTT parameters), LGA (fasting, 1- and 2-hour), gestational hypertension/preeclampsia 
(1-, 2- and 3-hour ), and shoulder dystocia (1- and 2-hour), as illustrated in figure 1. We 
found no evidence of an association between OGTT parameters and preeclampsia, SGA or 
neonatal hypoglycemia.
Comment
In a prospective study of women with mild glucose intolerance and fasting glucose <95 
mg/dL, we found evidence of a non-linear association between fasting glucose and 
gestational hypertension/preeclampsia, with an acceleration in risk for fasting glucose values 
from 85 through 94 mg/dL. We did not find evidence of a departure from linearity for 3-
hour OGTT parameters and other outcomes.
Our findings confirm and extend earlier work linking mild glucose intolerance with adverse 
perinatal outcomes. In the HAPO study 4, authors reported a direct association between 
fasting glucose and adverse pregnancy outcomes among women with fasting glucose < 105 
mg/dL and 2-hour, 75g OGTT < 200 mg/dL at 24 to 32 weeks’ gestation. Other authors 
have reported a linear increase in adverse outcomes with increasing 3-hour OGTT results 
among women without GDM by NDDG criteria8.
We found that almost all of the associations between blood glucose concentration and 
adverse pregnancy outcomes were linear. These results suggest that, within the range of 
concentrations we observed, there was no threshold below which the risk of adverse 
outcomes stopped decreasing, nor above which the risk remained stable. Rather, within this 
range, higher concentrations were always associated with increased risk of adverse outcome. 
Therefore, there is no "natural" cutoff to define gestational diabetes, and cutoff values 
should be based on the benefits versus the risks of treatment, as well as the burden to both 
the individual and the health care system of making a diagnosis of GDM.
Our finding that fasting glucose values of 85-94 mg/dL were more strongly associated with 
gHTN may reflect differences in the pathophysiology of fasting compared with post-load 
glucose intolerance. Fasting glucose reflects basal insulin secretion and hepatic insulin 
sensitivity. Post-load glucose regulation reflects increased insulin secretion and peripheral 
insulin sensitivity9, as well as diminished ability of insulin to suppress hepatic glucose 
production10. Our finding of a non-linear association between fasting glucose and 
gestational hypertension suggests that factors affecting basal insulin secretion and hepatic 
insulin sensitivity may also play a role in gestational hypertension. To the extent that 
STUEBE et al. Page 5













impaired fasting glucose is correlated with body mass index, these results may also reflect 
greater adiposity among women with higher fasting glucose values. In a prior analysis of the 
same group of women, we found that pregravid BMI was associated with risk of gestational 
hypertension, independent of glucose tolerance11.
Strengths of our study include standardized, prospective assessment of glucose tolerance and 
obstetrical outcomes. Our multicenter design includes women from 14 centers in the United 
States, increasing generalizability. Nevertheless, our findings must be interpreted in the 
context of the study design. This is a secondary analysis of participants in a clinical trial, and 
enrollment was limited to women with glucose loading test results of 135 to 199 mg/dL and 
fasting glucose < 95mg/dL. Our results are therefore only generalizable to women with mild 
glucose intolerance. This analysis does not address glycemic control, but rather the 
prognostic implications of results of the 3-hour OGTT, Multiple testing is also a concern. 
We tested for non-linear associations for 4 different glucose parameters and seven outcomes, 
and, with a p value of 0.05, we would expect at least one statistically significant result by 
chance alone. Further studies will be needed to confirm our findings in other patient 
populations.
In conclusion, we found tentative evidence of a non-linear association between fasting 
glucose and gestational hypertension/preeclampsia among women with mild gestational 
glucose intolerance. We found no evidence of any other threshold values in the 3-hour oral 
glucose tolerance test above which there is a non-linear increase in adverse perinatal 
outcomes.
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Non-parametric associations between OGTT values and pregnancy outcomes. The black line 
indicates the predicted probability of an outcome, and the grey region indicates the 95% 
confidence interval around that predicted probability. We found a statistically significant 
departure from linearity for fasting glucose and gestational hypertension/preeclampsia (top 
left), with an increase in the slope of the association for glucose values between 85 and 94 
mg/dL (top left). We found linear associations between 3-hour OGTT parameters and 
gestational hypertension/preeclampsia (1-, 2- and 3-hour ), the primary outcome (all OGTT 
parameters), LGA (fasting, 1- and 2-hour), and shoulder dystocia (1- and 2-hour).
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Table 1
Characteristics of the study population (N=1360)
N (%)
Race/Ethnicity
 Black 165 (12.1)
 White 362 (26.6)
 Hispanic 775 (57.0)
 Other 58 (4.3)
Nulliparous 448 (32.9)
BMI
Normal BMI (<25 kg/m2) 656 (48.2)
Overweight BMI (25-<30 kg/m2) 410 (30.2)
Obese BMI (≥30 kg/m2) 294 (21.6)
Mean (SD)
BMI (kg/m2) n=1250 26.6 (5.6)
Age, mean (SD) 27.9 (5.6)
Fasting glucose 85.3 (5.8)
1h glucose, mg/dL 166.9 (30.0)
2h glucose 144.2 (29.6)
3h glucose 116.9 (28.3)
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Table 2
Prevalence of outcomes of interest (N=1360)
Outcome N (%)
N 1360
Composite outcome 442 (33.9)
LGA 161 (11.9)
SGA 90 (6.6)
gHTN or preeclampsia 145 (10.7)
Preeclampsia 61 (4.5)
Shoulder dystocia 35 (2.6)
Hypoglycemia 175 (16.3)
Am J Perinatol. Author manuscript; available in PMC 2015 October 18.
